Nerbass Fabiana B, Lima Helbert do Nascimento, Thomé Fernando Saldanha, Vieira Neto Osvaldo Merege, Lugon Jocemir Ronaldo, Sesso Ricardo
Fundação Pró-Rim, Joinville, SC, Brasil.
Universidade da Região de Joinville, Joinville, SC, Brasil.
J Bras Nefrol. 2022 Jul-Sep;44(3):349-357. doi: 10.1590/2175-8239-JBN-2021-0198.
National data on chronic dialysis treatment are essential to support the development of health policies aimed at improving the treatment for thousands of people.
To report epidemiological data from the 2020 Brazilian Dialysis Survey, sponsored by the Brazilian Society of Nephrology.
A survey was carried out in Brazilian chronic dialysis centers using an online questionnaire for the year, covering clinical and epidemiological aspects of patients in a chronic dialysis program, data on dialysis therapy, characteristics of dialysis units and the impact of the COVID-19 pandemic.
235 (28%) of the centers responded to the questionnaire. In July 2020, the estimated total number of patients on dialysis was 144,779. The estimated prevalence and incidence rates of patients per million population (pmp) were 684 and 209, respectively. Of the prevalent patients, 92.6% were on hemodialysis (HD) and 7.4% were on peritoneal dialysis (PD); 23% were on the transplant waiting list. A central venous catheter was used by a quarter of patients on HD. The incidence rate of confirmed COVID-19 between February and July 2020 was 684/10,000 dialysis patients, and the lethality rate was 25.7%. The estimated overall mortality and COVID-19 crude annual mortality rates were 24.5 and 4.2%, respectively.
The absolute number of patients on chronic dialysis and prevalence rate continued to increase. The low use of PD as dialysis therapy was maintained and the use of long-term catheters for HD increased. The COVID-19 pandemic contributed to the increase in the overall mortality rate.
有关慢性透析治疗的全国性数据对于支持旨在改善数千人治疗情况的卫生政策的制定至关重要。
报告由巴西肾脏病学会赞助的2020年巴西透析调查的流行病学数据。
在巴西慢性透析中心开展了一项调查，使用年度在线问卷，涵盖慢性透析项目中患者的临床和流行病学方面、透析治疗数据、透析单位特征以及新冠疫情的影响。
235个（28%）中心回复了问卷。2020年7月，估计透析患者总数为144,779人。每百万人口（pmp）的患者估计患病率和发病率分别为684和209。在现患患者中，92.6%接受血液透析（HD），7.4%接受腹膜透析（PD）；23%在移植等待名单上。四分之一的HD患者使用中心静脉导管。2020年2月至7月期间确诊新冠的发病率为每10,000名透析患者684例，致死率为25.7%。估计的总体死亡率和新冠粗年死亡率分别为24.5%和4.2%。
慢性透析患者的绝对数量和患病率持续上升。PD作为透析治疗的低使用率持续存在，HD长期导管的使用增加。新冠疫情导致总体死亡率上升。
